DiaMedica Therapeutics Inc [DMAC] stock prices are down -1.26% to $3.93 at the moment. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The DMAC shares have gain 7.08% over the last week, with a monthly amount glided 11.97%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
DiaMedica Therapeutics Inc [NASDAQ: DMAC] stock has seen the most recent analyst activity on October 07, 2024, when H.C. Wainwright initiated its Buy rating and assigned the stock a price target of $7. On June 22, 2023, upgrade upgraded it’s rating to Outperform but maintained its price target of $7 on the stock. Oppenheimer started tracking the stock assigning a Outperform rating and suggested a price target of $27 on April 09, 2021. ROTH Capital initiated its recommendation with a Buy and recommended $38 as its price target on February 17, 2021. Guggenheim started tracking with a Buy rating for this stock on October 30, 2020, and assigned it a price target of $16. In a note dated July 08, 2020, Maxim Group initiated an Buy rating and provided a target price of $14 on this stock.
The stock price of DiaMedica Therapeutics Inc [DMAC] has been fluctuating between $3.19 and $6.82 over the past year. Currently, Wall Street analysts expect the stock to reach $8.33 within the next 12 months. DiaMedica Therapeutics Inc [NASDAQ: DMAC] shares were valued at $3.93 at the most recent close of the market. An investor can expect a potential return of 111.96% based on the average DMAC price forecast.
Analyzing the DMAC fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.7, Equity is -0.61 and Total Capital is -0.85. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It’s worth pointing out that DiaMedica Therapeutics Inc [NASDAQ:DMAC]’s Current Ratio is 8.02. In addition, the Quick Ratio stands at 8.02 and the Cash Ratio stands at 0.55.
